Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Vertex Pharmaceuticals Incorporated, Kymera Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Vertex Pharmaceuticals Incorporated, Kymera Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Vertex Pharmaceuticals Incorporated, Kymera Therapeutics and Inc.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Latest Biotechnology and Vertex Pharmaceuticals Incorporated, Kymera Therapeutics, Inc. Stock News

As of August 31, 2026, Vertex Pharmaceuticals Incorporated had a $138.0 billion market capitalization, compared to the Biotechnology median of $279.3 million. Vertex Pharmaceuticals Incorporated’s stock is NA in 2026, NA in the previous five trading days and up 38.89% in the past year.

Currently, Vertex Pharmaceuticals Incorporated’s price-earnings ratio is 31.7. Vertex Pharmaceuticals Incorporated’s trailing 12-month revenue is $12.6 billion with a 35.0% net profit margin. Year-over-year quarterly sales growth most recently was 12.5%. Analysts expect adjusted earnings to reach $19.037 per share for the current fiscal year. Vertex Pharmaceuticals Incorporated does not currently pay a dividend.

Currently, Kymera Therapeutics, Inc. does not have a price-earnings ratio. Kymera Therapeutics, Inc.’s trailing 12-month revenue is $105.0 million with a -285.3% net profit margin. Year-over-year quarterly sales growth most recently was 465.2%. Analysts expect adjusted earnings to reach $-3.785 per share for the current fiscal year. Kymera Therapeutics, Inc. does not currently pay a dividend.

How We Compare Vertex Pharmaceuticals Incorporated, Kymera Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Vertex Pharmaceuticals Incorporated, Kymera Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Vertex Pharmaceuticals Incorporated, Kymera Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Vertex Pharmaceuticals Incorporated	VRTX	C
Kymera Therapeutics, Inc.	KYMR	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Vertex Pharmaceuticals Incorporated has a Growth Score of 60, which is Average. Kymera Therapeutics, Inc. has a Growth Score of 10, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Vertex Pharmaceuticals Incorporated, Kymera Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Vertex Pharmaceuticals Incorporated, Kymera Therapeutics or Inc. is the better investment when it comes to sustainable growth.

Vertex Pharmaceuticals Incorporated, Kymera Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Vertex Pharmaceuticals Incorporated	VRTX	A
Kymera Therapeutics, Inc.	KYMR	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Vertex Pharmaceuticals Incorporated has a Momentum Score of 81, which is Very Strong. Kymera Therapeutics, Inc. has a Momentum Score of 97, which is Very Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Vertex Pharmaceuticals Incorporated, Kymera Therapeutics and Inc. have a grade of A. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Vertex Pharmaceuticals Incorporated, Kymera Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Vertex Pharmaceuticals Incorporated	VRTX	D
Kymera Therapeutics, Inc.	KYMR	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Vertex Pharmaceuticals Incorporated has a Earnings Estimate Score of 34, which is Negative. Kymera Therapeutics, Inc. has a Earnings Estimate Score of 31, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Vertex Pharmaceuticals Incorporated, Kymera Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Vertex Pharmaceuticals Incorporated, Kymera Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Vertex Pharmaceuticals Incorporated, Kymera Therapeutics and Inc. Grades

In addition to Momentum, Growth and Estimate Revisions, A+ Investor also provides grades for Value and Quality.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Vertex Pharmaceuticals Incorporated, Kymera Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Vertex Pharmaceuticals Incorporated, Kymera Therapeutics or Inc. Stock?

Overall, Vertex Pharmaceuticals Incorporated stock has a Growth Score of 60, Momentum Score of 81 and Estimate Revisions Score of 34.

Kymera Therapeutics, Inc. stock has a Growth Score of 10, Momentum Score of 97 and Estimate Revisions Score of 31.

Comparing Vertex Pharmaceuticals Incorporated, Kymera Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.